Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have successfully completed the previous double-blind study AGAL-008-00 (NCT00074984)~* Patients must provide written informed consent prior to study participation~* Female patients of childbearing potential must have a negative pregnancy test prior to each dosing and all female patients must use a medically accepted form of contraception throughout the study~Exclusion Criteria:~* The patient was unable to complete AGAL-008-00 (NCT00074984)~* The patient has undergone kidney transplantation or is currently on dialysis~* The patient has diabetes mellitus or presence of confounding renal disease~* The patient has a clinically significant organic disease or an unstable condition that precludes participation~* The patient is unwilling to comply with the protocol requirements

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fabrazyme 1.0 mg/kg every 2 weeks (Type: EXPERIMENTAL): This is an open-label extension study to AGAL-008-00 (NCT00074984) and all patients received Fabrazyme treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).